Musings on guidelines and evidence: A pragmatic and nephrocentric view

Peritoneal Dialysis International

Volumn 27, Issue 1, 2007, Pages 31-35

  Mendelsohn, David C ^a  

^a HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICODEXTRIN; MULTIVITAMIN; SEVELAMER;

ARTICLE; BIOCOMPATIBILITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS HEMODIALYSIS; COST BENEFIT ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MEDICAL PRACTICE; MEDICAL SOCIETY; MORTALITY; NEPHROLOGY; PATIENT CARE; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD;

HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PERITONEAL DIALYSIS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33947096407     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700106     Document Type: Article

References (26)

1. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Management of blood pressure in hemodialysis patients. J Am Soc Nephrol 2006; 17(3 Suppl 1):S8-10.
2. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Hemodialysis adequacy in adults. J Am Soc Nephrol 2006; 17(3 Suppl 1):S4-S7.
3. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Frequent and sustained hemodialysis. J Am Soc Nephrol 2006; 17(3 Suppl 1):S24-7.
4. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Vascular access. J Am Soc Nephrol 2006; 17(3 Suppl 1):S16-23.
5. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Mineral metabolism. J Am Soc Nephrol 2006; 17(3 Suppl 1):S11-15.
6. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(3 Suppl 1):S1-27.
7. Vaage-Nilsen O. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure, part III.2: Treatment of anaemia with iron. Nephrol Dial Transplant 2005; 20:1512-13.
8. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised European Best Practice Guidelines for the management ofanaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2):ii1-47.
9. CARI (Caring for Australians with Renal Impairment) Guidelines; 2006. Available at: http://www.cari.org.au/ckd_prevent_list_published.php
10. Chronic kidney disease in adults: UK guidelines for identification, managementand referral of adults. 10-6-2005. Available at: http://www.renal.org/CKDguide/full/Intro.htm
11. [No authors listed.] I. NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000 [Published erratum appears in Am J Kidney Dis 2005; 45:791]. Am J Kidney Dis 2001; 37(1 Suppl 1):S7-64.
12. [No authors listed.] II. NKF-K/DOQI clinical practice guidelines for peritoneal dialysis adequacy: update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1):S65-136.
13. [No authors listed.] III. NKF-K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1):S137-81.
14. [No authors listed.] IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000 [Published erratum appears in Am J Kidney Dis 2001; 38:442]. Am J Kidney Dis 2001; 37(1 Suppl 1):S182-238.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1-266.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1-201.
17. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(4 Suppl 3):S1-91.
18. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5 Suppl 1):S1-290.
19. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45(4 Suppl 3):S1-153.
20. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004; 15:411-19.
21. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normalas compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-90.
22. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-20.
23. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-19.
24. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
25. Genzyme Corporation. Genzyme announces positive results from DCOR trial favoring use of Renagel. 28-7-2005. Available at: http://www.renagel.com/ docs/DCOR_07_28_05.pdf
26. Fissell RB, Bragg-Gresham JL, Gillespie BW, Goodkin DA, Bommer J, Saito A, et al. International variation in vitamin prescription and association with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44:293-9.